Tianjin Lisheng Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 17.92%

Tianjin Lisheng Pharmaceutical Co Ltd (002393) has an Asset Resilience Ratio of 17.92% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Tianjin Lisheng Pharmaceutical Co Ltd to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CN¥991.31 Million
≈ $145.06 Million USD Cash + Short-term Investments

Total Assets

CN¥5.53 Billion
≈ $809.66 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2022–2025)

This chart shows how Tianjin Lisheng Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See 002393 net asset quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Tianjin Lisheng Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 002393 market cap overview.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥991.31 Million 17.92%
Total Liquid Assets CN¥991.31 Million 17.92%

Asset Resilience Insights

  • Good Liquidity Position: Tianjin Lisheng Pharmaceutical Co Ltd maintains a healthy 17.92% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Tianjin Lisheng Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Tianjin Lisheng Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 11.60%
SIMCERE PHARMAC. GRP LTD
F:S2P
Drug Manufacturers - Specialty & Generic 0.44%
Curaleaf Holdings Inc.
TO:CURA
Drug Manufacturers - Specialty & Generic 3.73%
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
Drug Manufacturers - Specialty & Generic 24.59%
Walvax BioTech
SHE:300142
Drug Manufacturers - Specialty & Generic 2.20%
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
Drug Manufacturers - Specialty & Generic 26.36%
Cronos Group Inc
TO:CRON
Drug Manufacturers - Specialty & Generic 69.94%
Renhe Pharmacy Co Ltd
SHE:000650
Drug Manufacturers - Specialty & Generic 37.54%

Annual Asset Resilience Ratio for Tianjin Lisheng Pharmaceutical Co Ltd (2022–2025)

The table below shows the annual Asset Resilience Ratio data for Tianjin Lisheng Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 18.27% CN¥1.02 Billion
≈ $149.30 Million
CN¥5.58 Billion
≈ $817.17 Million
+8.36pp
2024-12-31 9.91% CN¥573.36 Million
≈ $83.90 Million
CN¥5.79 Billion
≈ $846.60 Million
+5.91pp
2023-12-31 4.00% CN¥231.26 Million
≈ $33.84 Million
CN¥5.78 Billion
≈ $845.88 Million
+0.21pp
2022-12-31 3.79% CN¥200.32 Million
≈ $29.31 Million
CN¥5.29 Billion
≈ $774.25 Million
--
pp = percentage points

About Tianjin Lisheng Pharmaceutical Co Ltd

SHE:002393 China Drug Manufacturers - Specialty & Generic
Market Cap
$639.74 Million
CN¥4.37 Billion CNY
Market Cap Rank
#11172 Global
#3167 in China
Share Price
CN¥14.15
Change (1 day)
-0.21%
52-Week Range
CN¥14.00 - CN¥27.50
All Time High
CN¥46.19
About

Tianjin Lisheng Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products in China and internationally. The company offers pharmaceutical, traditional Chinese medicine, and antibiotic products in various forms, such as oral solid dosage forms, soft capsules, sterile preparations, and raw materials primarily for cardiovascular and digestive sy… Read more